PMID- 17726467
OWN - NLM
STAT- MEDLINE
DCOM- 20071019
LR  - 20220318
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 97
IP  - 6
DP  - 2007 Sep 17
TI  - PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of 
      phospho-Akt-negative breast carcinomas.
PG  - 809-17
AB  - We have used a novel variant of the human oestrogen receptor (ER)-positive MCF-7 
      cell line, TMX2-28, as a model to study breast cancer. TMX2-28 cells show no 
      detectable levels of mRNA or protein expression for the ER and express basal 
      cytokeratins (CKs) 5, 14, and 17. cDNA microarray comparison between TMX2-28 and 
      its parent cell line, MCF-7, identified 1402 differentially expressed 
      transcripts, one of which was, phospholipase D1 (PLD1). Using real-time RT-PCR, 
      we confirmed that PLD1 mRNA levels are 10-fold higher in TMX2-28 cells than in 
      MCF-7 cells. We next examined PLD1 expression in human breast carcinomas. 
      Phospholipase D1 mRNA levels were higher in breast tumours that expressed 
      high-mRNA levels of basal CKs 5 and/or 17, but PLD1 mRNA levels were not 
      significantly higher in ER-negative tumours. Phospholipase D1 protein was 
      overexpressed in 10 of 42 (24%) breast tumours examined by IHC. Phospholipase D1 
      was overexpressed in 6 of 31 ER-positive tumours and 4 of 11 ER-negative tumours. 
      Phospholipase D1 was overexpressed in three of the four tumours that showed high 
      CK5/17 expression. Five PLD1-positive tumours were negative for phospho-Akt 
      expression, but positive for phospho-mammalian target of rapamycin (mTOR) 
      expression. The other five PLD1-positive breast tumours showed positive 
      expression for phospho-Akt; however, only two of these cases were positive for 
      phospho-mTOR. In this study, we report that PLD1 and phospho-mTOR are coexpressed 
      in a subset of phospho-Akt-negative breast carcinomas.
FAU - Gozgit, J M
AU  - Gozgit JM
AD  - Department of Veterinary and Animal Sciences, University of Massachusetts, 
      Morrill 1 North, Amherst, MA 01003-9298, USA.
FAU - Pentecost, B T
AU  - Pentecost BT
FAU - Marconi, S A
AU  - Marconi SA
FAU - Ricketts-Loriaux, R S J
AU  - Ricketts-Loriaux RS
FAU - Otis, C N
AU  - Otis CN
FAU - Arcaro, K F
AU  - Arcaro KF
LA  - eng
GR  - R01 ES009795/ES/NIEHS NIH HHS/United States
GR  - K02 ES000384/ES/NIEHS NIH HHS/United States
GR  - R01 ES09795/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20070828
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (DNA, Complementary)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Estrogen)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Oncogene Protein v-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.1.4.4 (Phospholipase D)
RN  - EC 3.1.4.4 (phospholipase D1)
SB  - IM
MH  - Blotting, Western
MH  - Breast Neoplasms/*enzymology/metabolism
MH  - Cell Line, Tumor
MH  - DNA, Complementary/metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Microarray Analysis
MH  - Oncogene Protein v-akt/metabolism
MH  - Phospholipase D/genetics/*metabolism
MH  - Protein Kinases/*metabolism
MH  - RNA, Messenger/metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - TOR Serine-Threonine Kinases
MH  - Up-Regulation
PMC - PMC2360386
EDAT- 2007/08/30 09:00
MHDA- 2007/10/20 09:00
PMCR- 2008/09/11
CRDT- 2007/08/30 09:00
PHST- 2007/08/30 09:00 [pubmed]
PHST- 2007/10/20 09:00 [medline]
PHST- 2007/08/30 09:00 [entrez]
PHST- 2008/09/11 00:00 [pmc-release]
AID - 6603926 [pii]
AID - 10.1038/sj.bjc.6603926 [doi]
PST - ppublish
SO  - Br J Cancer. 2007 Sep 17;97(6):809-17. doi: 10.1038/sj.bjc.6603926. Epub 2007 Aug 
      28.